NZ333497A - High dose liposomal aerosol formulations comprising cyclosporin A or budesonide - Google Patents
High dose liposomal aerosol formulations comprising cyclosporin A or budesonideInfo
- Publication number
- NZ333497A NZ333497A NZ333497A NZ33349797A NZ333497A NZ 333497 A NZ333497 A NZ 333497A NZ 333497 A NZ333497 A NZ 333497A NZ 33349797 A NZ33349797 A NZ 33349797A NZ 333497 A NZ333497 A NZ 333497A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cyclosporin
- budesonide
- aerosol composition
- liposome
- high dose
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 147
- 239000000203 mixture Substances 0.000 title claims abstract description 123
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 110
- 229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 110
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 110
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 110
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 title claims abstract description 35
- 229960004436 budesonide Drugs 0.000 title claims abstract description 35
- 238000009472 formulation Methods 0.000 title description 64
- 239000002502 liposome Substances 0.000 claims abstract description 137
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 33
- 208000019693 Lung disease Diseases 0.000 claims abstract description 13
- 230000001404 mediated effect Effects 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 21
- 206010020751 Hypersensitivity Diseases 0.000 claims description 10
- 208000006673 asthma Diseases 0.000 claims description 10
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 5
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 5
- 230000009610 hypersensitivity Effects 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 230000000843 anti-fungal effect Effects 0.000 claims description 4
- 210000002969 egg yolk Anatomy 0.000 claims description 4
- 235000013345 egg yolk Nutrition 0.000 claims description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 59
- 239000003814 drug Substances 0.000 description 33
- 229940079593 drug Drugs 0.000 description 31
- 229930182912 cyclosporin Natural products 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 28
- 210000004072 lung Anatomy 0.000 description 28
- 239000006199 nebulizer Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 235000011468 Albizia julibrissin Nutrition 0.000 description 23
- 241001070944 Mimosa Species 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- 238000002663 nebulization Methods 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000003862 glucocorticoid Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000003643 water by type Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229940037128 systemic glucocorticoids Drugs 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 102000003896 Myeloperoxidases Human genes 0.000 description 3
- 108090000235 Myeloperoxidases Proteins 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 238000004513 sizing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000001370 mediastinum Anatomy 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 206010051604 Lung transplant rejection Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000035565 breathing frequency Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical group [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical group 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67565496A | 1996-07-03 | 1996-07-03 | |
| US08/731,605 US5958378A (en) | 1996-07-03 | 1996-10-16 | High dose liposomal aerosol formulations containing cyclosporin A or budesonide |
| PCT/US1997/011696 WO1998000111A1 (en) | 1996-07-03 | 1997-07-02 | High dose liposomal aerosol formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ333497A true NZ333497A (en) | 2000-06-23 |
Family
ID=27101390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ333497A NZ333497A (en) | 1996-07-03 | 1997-07-02 | High dose liposomal aerosol formulations comprising cyclosporin A or budesonide |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0959874B1 (https=) |
| JP (1) | JP2001524930A (https=) |
| CN (1) | CN1094345C (https=) |
| AT (2) | ATE268163T1 (https=) |
| AU (1) | AU732124B2 (https=) |
| CA (1) | CA2259185C (https=) |
| DE (2) | DE69729391T2 (https=) |
| NZ (1) | NZ333497A (https=) |
| TW (1) | TW497974B (https=) |
| WO (1) | WO1998000111A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013027042A1 (en) | 2011-08-19 | 2013-02-28 | Nufarm Uk Limited | Novel inhibitor compositions and methods of use |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417172B1 (en) * | 1995-06-05 | 2002-07-09 | Eisai Co., Ltd. | Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| US5863910A (en) * | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
| US7348025B2 (en) | 1997-09-23 | 2008-03-25 | Research Development Foundation | Small particle liposome aerosols for delivery of anticancer drugs |
| US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US20020006901A1 (en) * | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
| NZ515644A (en) * | 1999-06-04 | 2004-12-24 | Skyepharma Inc | Oil-core compositions for the sustained release of hydrophobic drugs |
| EP1242106A4 (en) * | 1999-12-04 | 2008-08-27 | Res Dev Foundation | IMPROVING INHALATION THERAPY USING CARBON GAS |
| PT1280520E (pt) | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| PT1458360E (pt) | 2001-12-19 | 2011-07-13 | Novartis Ag | Derivados de indole como agonistas do recetor s1p1 |
| EP1506032A1 (en) * | 2002-05-20 | 2005-02-16 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| US20050255154A1 (en) | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
| PL1888033T3 (pl) | 2005-06-09 | 2014-09-30 | Meda Ab | Sposób i kompozycja do leczenia chorób zapalnych |
| DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| CN101502484B (zh) * | 2006-12-26 | 2011-04-20 | 济南康泉医药科技有限公司 | 同载糖皮质激素和化疗药物的抗癌缓释剂 |
| CA2705159A1 (en) * | 2007-11-09 | 2009-05-14 | Map Pharmaceuticals, Inc. | Methods for administering corticosteroid formulations |
| SG10202010355PA (en) | 2010-03-12 | 2020-11-27 | Berg Llc | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| US9144575B2 (en) | 2010-07-28 | 2015-09-29 | Life Technologies Corporation | Anti-viral azide containing compounds |
| US20120028335A1 (en) | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti-viral azide-containing compounds |
| IN2013MN00329A (https=) * | 2010-08-05 | 2015-05-29 | Piramal Entpr Ltd | |
| CN102008713B (zh) * | 2010-12-02 | 2012-10-24 | 深圳海王药业有限公司 | 环孢素a前体脂质体、药物组合物及其制备方法 |
| EP2720680B1 (en) * | 2011-06-17 | 2020-02-12 | Berg LLC | Inhalable pharmaceutical compositions |
| AU2013212068B2 (en) | 2012-01-26 | 2018-02-15 | Life Technologies Corporation | Methods for increasing the infectivity of viruses |
| EA202092893A1 (ru) | 2018-06-27 | 2021-04-19 | Брес Терапьютикс Гмбх | Фармацевтические композиции в лиофилизированной форме |
| JP7526103B2 (ja) * | 2018-06-27 | 2024-07-31 | ブレス テラポイティクス ゲーエムベーハー | 大環状免疫抑制剤を含む吸入用組成物 |
| EA202092892A1 (ru) * | 2018-12-04 | 2021-05-27 | Брес Терапьютикс Гмбх | Ингаляционные композиции, содержащие макроциклические иммуносупрессанты |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8403905D0 (sv) * | 1984-07-30 | 1984-07-30 | Draco Ab | Liposomes and steroid esters |
| SE8603812D0 (sv) * | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
| IE63869B1 (en) * | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| MX9201782A (es) * | 1991-04-19 | 1992-10-01 | Sandoz Ag | Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene. |
| DE4203306A1 (de) * | 1992-02-06 | 1993-08-12 | Ig Spruehtechnik Gmbh | Asthma oder pulmonal-aerosolzubereitungen mit lecithin |
| AR002009A1 (es) * | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
-
1997
- 1997-02-17 TW TW086101859A patent/TW497974B/zh not_active IP Right Cessation
- 1997-07-02 CA CA002259185A patent/CA2259185C/en not_active Expired - Fee Related
- 1997-07-02 EP EP97933287A patent/EP0959874B1/en not_active Expired - Lifetime
- 1997-07-02 JP JP50449998A patent/JP2001524930A/ja active Pending
- 1997-07-02 CN CN97196141A patent/CN1094345C/zh not_active Expired - Fee Related
- 1997-07-02 AT AT97933287T patent/ATE268163T1/de not_active IP Right Cessation
- 1997-07-02 AT AT04009645T patent/ATE328583T1/de not_active IP Right Cessation
- 1997-07-02 NZ NZ333497A patent/NZ333497A/en not_active IP Right Cessation
- 1997-07-02 WO PCT/US1997/011696 patent/WO1998000111A1/en not_active Ceased
- 1997-07-02 DE DE69729391T patent/DE69729391T2/de not_active Expired - Lifetime
- 1997-07-02 DE DE69736083T patent/DE69736083T2/de not_active Expired - Lifetime
- 1997-07-02 AU AU36508/97A patent/AU732124B2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013027042A1 (en) | 2011-08-19 | 2013-02-28 | Nufarm Uk Limited | Novel inhibitor compositions and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69729391D1 (de) | 2004-07-08 |
| AU732124B2 (en) | 2001-04-12 |
| CN1224347A (zh) | 1999-07-28 |
| WO1998000111A1 (en) | 1998-01-08 |
| DE69736083T2 (de) | 2006-12-28 |
| AU3650897A (en) | 1998-01-21 |
| ATE268163T1 (de) | 2004-06-15 |
| DE69729391T2 (de) | 2005-06-02 |
| ATE328583T1 (de) | 2006-06-15 |
| JP2001524930A (ja) | 2001-12-04 |
| CA2259185A1 (en) | 1998-01-08 |
| CA2259185C (en) | 2009-12-15 |
| TW497974B (en) | 2002-08-11 |
| DE69736083D1 (de) | 2006-07-20 |
| CN1094345C (zh) | 2002-11-20 |
| EP0959874B1 (en) | 2004-06-02 |
| EP0959874A4 (https=) | 1999-12-22 |
| EP0959874A1 (en) | 1999-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5958378A (en) | High dose liposomal aerosol formulations containing cyclosporin A or budesonide | |
| CA2259185C (en) | High dose liposomal aerosol formulations | |
| US5049389A (en) | Novel liposome composition for the treatment of interstitial lung diseases | |
| Niven et al. | Nebulization of liposomes. I. Effects of lipid composition | |
| US5192528A (en) | Corticosteroid inhalation treatment method | |
| US5043165A (en) | Novel liposome composition for sustained release of steroidal drugs | |
| US6544542B1 (en) | Fat emulsions for inhalational administration | |
| JP6357481B2 (ja) | プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法 | |
| US20070065369A1 (en) | Novel methods and composition for delivering macromolecules to or via the respiratory tract | |
| US20050025822A1 (en) | Method of pulmonary administration of an agent | |
| CN111249260A (zh) | 包含rpl554的液体吸入制剂 | |
| WO2015138423A9 (en) | Prostacylin compositions and methods for using the same | |
| EP0195809A1 (en) | A liposomal sustained-release aerosol delivery system | |
| WO1990006775A1 (en) | A novel nonphospholipid liposome composition for sustained release of drugs | |
| Waldrep et al. | Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition | |
| Waldrep et al. | Nebulized glucocorticoids in liposomes: aerosol characteristics and human dose estimates | |
| Waldrep et al. | High dose cyclosporin A and budesonide-liposome aerosols. | |
| US20020076383A1 (en) | Composition and method for treatment of otitis external | |
| RU2174390C2 (ru) | Высокодозированные липосомные аэрозольные фармацевтические композиции | |
| KR100497564B1 (ko) | 고용량의리포좀에어로졸제제 | |
| US20020090344A1 (en) | Composition and method for decreasing upper respiratory airway resistance | |
| CN114126600B (zh) | 三苯乙酸维兰特罗的脂质体制剂 | |
| CN116687855B (zh) | 电解还原离子水在脂类物质及其组合物的复溶、分散或雾化中的用途 | |
| Khale et al. | Liposomal Nebulising Solutions of Salbutamol Sulphate-A Characterisation Study | |
| CN121313612A (zh) | 一种长效干粉微球吸入剂及制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |